Claus Brandt1, Rasmus Hvass Hansen2, Jakob Bondo Hansen3, Caroline Holkmann Olsen4, Pia Galle1, Thomas Mandrup-Poulsen5, Julie Gehl6, Bente Klarlund Pedersen1, Pernille Hojman7. 1. The Centre of Inflammation and Metabolism and the Centre for Physical Activity Research, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Denmark, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. 2. Research Group, Dept. of Radiology, Copenhagen University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark. 3. Immunoendocrinology lab, Section of Endocrinological Research, Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen, Denmark. 4. Department of Pathology, Copenhagen University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark. 5. Immunoendocrinology lab, Section of Endocrinological Research, Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen, Denmark; Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Solna, SE-171 76, Stockholm, Sweden. 6. Department of Oncology, Copenhagen University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark. 7. The Centre of Inflammation and Metabolism and the Centre for Physical Activity Research, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Denmark, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. Electronic address: phojman@inflammation-metabolism.dk.
Abstract
OBJECTIVE: Follistatin-like 3 (fstl3), a natural inhibitor of members of the TGF-β family, increases during resistance training in human plasma. Fstl3 primarily binds myostatin and activin A, and thereby inhibits their functions. We hypothesize that blocking myostatin and activin A signalling through systemic fstl3 over-expression protects against diet-induced obesity and insulin resistance. METHODS: Fstl3 was over-expressed by DNA electrotransfer in tibialis anterior, quadriceps and gastrocnemius muscles in female C57BL/C mice, and the mice were subsequently randomized to chow or high-fat feeding. Body weight, food intake, fat accumulation by MR scanning, and glucose, insulin and glucagon tolerance were evaluated, as was the response in body weight and metabolic parameters to 24h fasting. Effects of fstl3 on pancreatic insulin and glucagon content, and pancreatic islet morphology were determined. RESULTS: Fstl3 over-expression reduced fat accumulation during high-fat feeding by 16%, and liver fat by 50%, as determined by MRI. No changes in body weight were observed, while the weight of the transfected muscles increased by 10%. No transcriptional changes were found in the subcutaneous adipose tissue. Fstl3 mice displayed improved insulin sensitivity and muscle insulin signalling. In contrast, glucose tolerance was impaired in high-fat fed fstl3 mice, which was explained by increased hepatic glucagon sensitivity and glucose output, as well as a decrease in the pancreatic insulin/glucagon ratio. Accordingly, fstl3 transfection improved counter-regulation to 24h fasting. CONCLUSION: Fstl3 over-expression regulates insulin and glucagon sensitivities through increased muscular insulin action, as well as increased hepatic glucagon sensitivity and pancreatic glucagon content.
OBJECTIVE:Follistatin-like 3 (fstl3), a natural inhibitor of members of the TGF-β family, increases during resistance training in human plasma. Fstl3 primarily binds myostatin and activin A, and thereby inhibits their functions. We hypothesize that blocking myostatin and activin A signalling through systemic fstl3 over-expression protects against diet-induced obesity and insulin resistance. METHODS:Fstl3 was over-expressed by DNA electrotransfer in tibialis anterior, quadriceps and gastrocnemius muscles in female C57BL/C mice, and the mice were subsequently randomized to chow or high-fat feeding. Body weight, food intake, fat accumulation by MR scanning, and glucose, insulin and glucagon tolerance were evaluated, as was the response in body weight and metabolic parameters to 24h fasting. Effects of fstl3 on pancreatic insulin and glucagon content, and pancreatic islet morphology were determined. RESULTS:Fstl3 over-expression reduced fat accumulation during high-fat feeding by 16%, and liver fat by 50%, as determined by MRI. No changes in body weight were observed, while the weight of the transfected muscles increased by 10%. No transcriptional changes were found in the subcutaneous adipose tissue. Fstl3mice displayed improved insulin sensitivity and muscle insulin signalling. In contrast, glucose tolerance was impaired in high-fat fed fstl3mice, which was explained by increased hepatic glucagon sensitivity and glucose output, as well as a decrease in the pancreatic insulin/glucagon ratio. Accordingly, fstl3 transfection improved counter-regulation to 24h fasting. CONCLUSION:Fstl3 over-expression regulates insulin and glucagon sensitivities through increased muscular insulin action, as well as increased hepatic glucagon sensitivity and pancreaticglucagon content.
Authors: J Nam; P Perera; R Gordon; Y H Jeong; A D Blazek; D G Kim; B C Tee; Z Sun; T D Eubank; Y Zhao; B Lablebecioglu; S Liu; A Litsky; N L Weisleder; B S Lee; T Butterfield; A L Schneyer; S Agarwal Journal: Bone Date: 2015-04-30 Impact factor: 4.398
Authors: Wagner S Dantas; Hamilton Roschel; Igor H Murai; Saulo Gil; Gangarao Davuluri; Christopher L Axelrod; Sujoy Ghosh; Susan S Newman; Hui Zhang; Samuel K Shinjo; Willian das Neves; Carlos Merege-Filho; Walcy R Teodoro; Vera L Capelozzi; Rosa Maria Pereira; Fabiana B Benatti; Ana L de Sá-Pinto; Roberto de Cleva; Marco A Santo; John P Kirwan; Bruno Gualano Journal: Diabetes Date: 2020-05-14 Impact factor: 9.461
Authors: Stephen M Cornish; Eric M Bugera; Todd A Duhamel; Jason D Peeler; Judy E Anderson Journal: Eur J Appl Physiol Date: 2020-03-06 Impact factor: 3.078
Authors: Katharina Timper; Almudena Del Río-Martín; Anna Lena Cremer; Stephan Bremser; Jens Alber; Patrick Giavalisco; Luis Varela; Christian Heilinger; Hendrik Nolte; Aleksandra Trifunovic; Tamas L Horvath; Peter Kloppenburg; Heiko Backes; Jens C Brüning Journal: Cell Metab Date: 2020-05-19 Impact factor: 27.287